The evolution of assays for immuno-oncology research
Drug Discovery World
FEBRUARY 15, 2023
These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Strategic Market Research Report; Immuno-oncology Assays Market Size, Trend Analysis 2030.
130 
Let's personalize your content